Kymera Therapeutics, Inc.
Kymera Therapeutics raised $656.1 million through offering.
1 source·10/12, 22:18·sec.gov
KT-621 clinical trial results show promising efficacy.
2 sources·08/12, 13:48·sec.gov
10-Q form submitted!
1 source·04/11, 13:03·sec.gov
Kymera announces quarterly financial results.
1 source·04/11, 12:14·sec.gov
Chiniara retires, Adams appointed as new CLO.
1 source·03/09, 11:12·sec.gov
10-Q form submitted!
1 source·11/08, 11:18·sec.gov
Kymera announces Q2 2025 financial results.
1 source·11/08, 11:12·sec.gov
Kymera Therapeutics announces a $237.3 million offering.
1 source·27/06, 20:58·sec.gov
Shareholder meeting results show routine governance decisions.
1 source·27/06, 20:34·sec.gov
Kymera advances KT-485 into clinical studies with Sanofi.
1 source·25/06, 11:14·sec.gov
Kymera Therapeutics Announces First Quarter 2025 Financial Results and Provides a Business Update
·finviz.com·09/05, 11:18